Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired_by |
gptkb:Novartis
|
| gptkbp:acquisition |
gptkb:Aton_Pharma
gptkb:Hexal_AG gptkb:Eon_Labs |
| gptkbp:acquisition_year |
gptkb:2003
|
| gptkbp:brand_recognition |
high brand recognition
|
| gptkbp:business_model |
committed to ethical standards
|
| gptkbp:clinical_trial |
conducts clinical research studies
conducts numerous |
| gptkbp:collaborations |
with academic institutions
engages in research collaborations |
| gptkbp:cultural_diversity |
promotes diversity in workforce
|
| gptkbp:customer_base |
serves healthcare providers
|
| gptkbp:customer_satisfaction |
focuses on customer satisfaction
|
| gptkbp:distribution_channels |
extensive distribution network
|
| gptkbp:employees |
over 25,000
|
| gptkbp:financial_performance |
strong financial performance
|
| gptkbp:focus |
affordable medicines
|
| gptkbp:formed |
gptkb:Novartis
|
| gptkbp:founded |
1886
|
| gptkbp:founder |
Fridolin Schmid
|
| gptkbp:global_presence |
over 140 countries
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
gptkb:Holzkirchen,_Germany |
| https://www.w3.org/2000/01/rdf-schema#label |
Sandoz
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
focuses on advanced manufacturing
|
| gptkbp:invention |
holds many patents
|
| gptkbp:market |
ensures market access for products
|
| gptkbp:market_launch |
frequently launches new products
|
| gptkbp:market_position |
leading generic pharmaceutical company
|
| gptkbp:merged_with |
gptkb:Ciba-Geigy
|
| gptkbp:parent_company |
gptkb:Novartis
|
| gptkbp:partnerships |
various healthcare organizations
with NGOs with governments with other pharmaceutical companies |
| gptkbp:product_quality |
maintains high quality standards
|
| gptkbp:production_location |
operates multiple facilities
|
| gptkbp:products |
generic drugs
biosimilars |
| gptkbp:regulatory_compliance |
obtains worldwide
|
| gptkbp:research_and_development |
invests heavily
|
| gptkbp:research_areas |
oncology
central nervous system dermatology hormonal therapies pain management urology gastroenterology cardiovascular respiratory anti-infectives |
| gptkbp:revenue |
approximately $10 billion
|
| gptkbp:social_responsibility |
engages in community support
|
| gptkbp:supply_chain |
global supply chain management
optimizes supply chain processes |
| gptkbp:sustainability_initiatives |
environmental responsibility
|
| gptkbp:training |
provides training programs
|
| gptkbp:trends |
adapts to market trends
|
| gptkbp:website |
www.sandoz.com
|
| gptkbp:bfsParent |
gptkb:Pfizer
gptkb:Novartis |
| gptkbp:bfsLayer |
4
|